NasdaqGM:ALVOBiotechs
Does Alvotech’s (ALVO) Reaffirmed 2026 Revenue Target Redefine Its Biosimilar Strategy Narrative?
Alvotech has published its 2025 Annual Report and filed its Form 20-F, detailing progress in its biosimilar portfolio, including five approved products and a pipeline of nine additional candidates supported by global commercial partnerships.
The company also reaffirmed its 2026 revenue guidance of US$650 million to US$700 million, highlighting a focus on cash flow and margin expansion through sales growth and operational efficiencies.
With reaffirmed 2026 revenue guidance and expanded...